Eisai and Biogen win approval for once-monthly Leqembi dosenews2025-01-27T00:03:18+00:00January 27th, 2025|Endpoints News|
Merck and Eisai reveal late-stage fail for Keytruda and Lenvima in gastroesophageal cancernews2025-01-24T20:00:55+00:00January 24th, 2025|Endpoints News|
Takeda discontinues US supply of gout drug Uloricnews2025-01-24T17:03:44+00:00January 24th, 2025|Endpoints News|
AstraZeneca allocates $570M for Canadian expansion, looks to add 700 new jobsnews2025-01-24T13:39:49+00:00January 24th, 2025|Endpoints News|
As another Trump term gets underway, pharma advisors get comfortable with uncertaintynews2025-01-23T20:35:28+00:00January 23rd, 2025|Endpoints News|
Teva, Astellas plan to participate in IRA drug price negotiationsnews2025-01-23T20:23:09+00:00January 23rd, 2025|Endpoints News|
Purdue, Sacklers reach new $7.4B opioid settlement after SCOTUS rejectionnews2025-01-23T20:01:12+00:00January 23rd, 2025|Endpoints News|
Teva’s MS drug and generics to add black box warning for anaphylaxisnews2025-01-23T11:16:21+00:00January 23rd, 2025|Endpoints News|
AstraZeneca exec stresses Calquence’s patent life ahead of next Medicare negotiationsnews2025-01-22T20:39:55+00:00January 22nd, 2025|Endpoints News|
Vanda loses constitutional fight over FDA’s drug talks with competitorsnews2025-01-22T20:31:17+00:00January 22nd, 2025|Endpoints News|
